AU Patent

AU2020352668A1 — Use of FGFR inhibitors in FGFR-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings

Assigned to Janssen Pharmaceutica NV · Expires 2022-03-31 · 4y expired

What this patent protects

Embodiments of the present invention relate to a method of treating cancer in a patient comprising administering an immune checkpoint inhibitor to the patient, wherein the patient has been diagnosed with an FGFR-genetically altered cancer, and has been pre-treated with an FGFR in…

USPTO Abstract

Embodiments of the present invention relate to a method of treating cancer in a patient comprising administering an immune checkpoint inhibitor to the patient, wherein the patient has been diagnosed with an FGFR-genetically altered cancer, and has been pre-treated with an FGFR inhibitor, such as erdafitinib.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020352668A1
Jurisdiction
AU
Classification
—
Expires
2022-03-31
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.